• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Virol . Molecular point-of-care testing versus conventional RT-PCR for influenza A: Diagnostic performance, clinical decision-making, and costs

tetano

Editor, Senior Moderator
J Clin Virol

. 2026 Sep 16:187:106005.
doi: 10.1016/j.jcv.2026.106005. Online ahead of print.

Molecular point-of-care testing versus conventional RT-PCR for influenza A: Diagnostic performance, clinical decision-making, and costs in a tertiary hospital in Shenzhen, China​


Feidi Ye 1 , Qiaoruo Jin 1 , Houming Liu 1 , Yunjian Ma 1 , Sheng Yu 1 , Yang Yang 2 , Jiuxin Qu 3

Affiliations


Abstract​


Background: Rapid diagnosis of influenza A is important for timely treatment and clinical management. However, evidence on the real-world clinical and economic utility of molecular point-of-care testing (POCT) remains limited, particularly in China.


Methods: This retrospective study was conducted at a tertiary hospital in Shenzhen, China. A performance validation study included 300 fever-clinic patients tested by both molecular POCT and conventional real-time reverse transcription polymerase chain reaction (RT-PCR) from April to May 2024. An application study compared 1021 patients tested by conventional RT-PCR from January to March 2024 with 4210 patients tested by molecular POCT from January to March 2025. Outcomes included diagnostic concordance, turnaround time (TAT), medication use, direct medical costs, and user satisfaction.


Results: Molecular POCT showed 100% concordance with conventional RT-PCR in the validation cohort, with 100% positive, negative, and overall agreement (Cohen's κ = 1.00). In the application study, median TAT was markedly shorter with POCT than with conventional RT-PCR, at 51 (IQR 44-60) min vs. 555 (IQR 370-1328) min (p < 0.001). Among patients receiving antivirals, etiological confirmation before prescription was more frequent in the POCT group than in the conventional RT-PCR group (58.0% vs. 31.7%; p < 0.001). Overall antiviral use was lower in the POCT group (44.4% vs. 55.2%; p < 0.001), whereas antibiotic use was higher (47.6% vs. 36.4%; p < 0.001), mainly among influenza A-negative patients. Total medical costs were lower in the POCT group, at 440.12 (IQR 347.35-606.01) vs. 613.44 (IQR 480.70-748.93) Chinese yuan (CNY) (p < 0.001), mainly because of reduced laboratory fees. Satisfaction with POCT was high among both patients and healthcare providers.


Conclusions: Molecular POCT for influenza A showed diagnostic accuracy comparable to conventional RT-PCR while substantially shortening TAT, supporting more etiologically informed antiviral prescribing, and reducing direct medical costs in routine clinical practice. Its effect on antibiotic prescribing, however, was less predictable.

Keywords: Diagnostic performance; Health economic evaluation; Influenza A virus; Molecular point-of-care testing; Real-time reverse transcription PCR.
 
Back
Top Bottom